Get the Stockscreener App
40.72
0.83%
0.335
Crispr Therapeutics Ag stock is traded at $40.72, with a volume of 3.08M.
It is up +0.83% in the last 24 hours and down -13.84% over the past month.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
See More
Previous Close:
$40.38
Open:
$40.25
24h Volume:
3.08M
Relative Volume:
2.01
Market Cap:
$3.48B
Revenue:
$170.10M
Net Income/Loss:
$-239.59M
P/E Ratio:
-9.1096
EPS:
-4.47
Net Cash Flow:
$-191.20M
1W Performance:
-6.99%
1M Performance:
-13.84%
6M Performance:
-31.68%
1Y Performance:
-33.04%
1-Day Range:
$39.41
$41.02
1-Week Range:
$39.41
$45.16
52-Week Range:
$39.41
$91.10
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Name
Crispr Therapeutics Ag
Sector
Industry
Phone
(617) 315-4600
Address
BAARERSTRASSE 14, ZUG
Compare CRSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
40.72 | 3.48B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-24 | Reiterated | Needham | Buy |
| Aug-02-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | Guggenheim | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-27-23 | Initiated | Mizuho | Buy |
| Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
| May-30-23 | Initiated | William Blair | Outperform |
| Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Mar-07-23 | Initiated | Robert W. Baird | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
| Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
| Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-10-20 | Reiterated | Needham | Buy |
| Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Jul-28-20 | Reiterated | Needham | Buy |
| Jul-14-20 | Initiated | SunTrust | Buy |
| Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-01-19 | Initiated | Jefferies | Buy |
| Jul-26-19 | Initiated | Canaccord Genuity | Buy |
| Jun-10-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-14-19 | Initiated | William Blair | Mkt Perform |
| Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
Crispr Therapeutics Ag Stock (CRSP) Latest News
1 Reason to Sell DexCom Stock, and 1 Reason to Buy - The Motley Fool
Intellia Crashes 60% in a Year: How Should You Play the Stock? - Yahoo Finance
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year - Investing.com
JMP Securities Reaffirms "Market Outperform" Rating for CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Hits New 12-Month LowTime to Sell? - MarketBeat
3 Things You Need to Know if You Buy CRISPR Therapeutics Today - MSN
3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) Sees Significant Decline in Short Interest - MarketBeat
State Street Corp Acquires 599,304 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Sets New 1-Year LowShould You Sell? - MarketBeat
3 Things You Need To Know If You Buy CRISPR Therapeutics Today - Barchart
CRISPR Therapeutics stock hits 52-week low at $43.37 - Investing.com
Zacks Research Issues Negative Forecast for CRSP Earnings - MarketBeat
Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers? - Insider Monkey
Catherine Wood's Strategic Acquisition of CRISPR Therapeutics AG Shares - GuruFocus.com
What is William Blair's Forecast for CRSP FY2024 Earnings? - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from Chardan Capital - MarketBeat
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewswire
CRISPR's CTX112 Cancer Therapy Shows 67% Response Rate in Clinical Trial, Earns FDA Special Status - StockTitan
XTX Topco Ltd Grows Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Main Management ETF Advisors LLC Purchases Shares of 14,744 CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
2 Biotech Stocks to Buy Hand Over Fist in December - AOL
CRISPR Therapeutics (CRSP) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report? - MSN
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Benjamin Edwards Inc. - MarketBeat
Wall Street Analysts Think CRISPR Therapeutics (CRSP) Could Surge 58.3%: Read This Before Placing a Bet - MSN
January 2025 Options Now Available For CRISPR Therapeutics (CRSP) - Nasdaq
Future-Proofing Growth of Gene Editing Technology Innovation - openPR
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by BNP Paribas Financial Markets - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Fmr LLC - MarketBeat
Crispr Therapeutics CEO Kulkarni sells $826,564 in shares By Investing.com - Investing.com Nigeria
Crispr Therapeutics CEO Kulkarni sells $826,564 in shares - Investing.com India
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Rating of "Hold" from Analysts - MarketBeat
CRISPR Therapeutics: Strong Balance Sheet Supports Ambitious Plans Amid Slow Growth - Seeking Alpha
CRISPR Technology Market Growth Trends from 2024 to 2033 | Key - openPR
Baker BROS. Advisors LP Boosts Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Zacks Research Has Bullish Forecast for CRSP FY2024 Earnings - MarketBeat
Loomis Sayles & Co. L P Trims Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? - Yahoo Finance
Learn to Evaluate (CRSP) using the Charts - Stock Traders Daily
Why Is CRISPR Therapeutics AG (CRSP) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey
CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell? - MSN
Crispr Therapeutics Ag Stock (CRSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):